Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 413169, 10 pages
http://dx.doi.org/10.1155/2015/413169
Review Article

Current Status of Research on Osteoporosis after Solid Organ Transplantation: Pathogenesis and Management

Center of Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha 410011, China

Received 17 August 2015; Revised 29 October 2015; Accepted 29 October 2015

Academic Editor: Rita Rezzani

Copyright © 2015 Gong-bin Lan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T.-M. Yu, C.-L. Lin, S.-N. Chang, F.-C. Sung, S.-T. Huang, and C.-H. Kao, “Osteoporosis and fractures after solid organ transplantation: a nationwide population-based cohort study,” Mayo Clinic Proceedings, vol. 89, no. 7, pp. 888–895, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. R. N. J. de Nijs, J. W. G. Jacobs, J. W. J. Bijlsma et al., “Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis,” Rheumatology, vol. 40, no. 12, pp. 1375–1383, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. B. B. Kalpakcioglu, K. Engelke, and H. K. Genant, “Advanced imaging assessment of bone fragility in glucocorticoid-induced osteoporosis,” Bone, vol. 48, no. 6, pp. 1221–1231, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. P. R. Ebeling, “Approach to the patient with transplantation-related bone loss,” The Journal of Clinical Endocrinology & Metabolism, vol. 94, no. 5, pp. 1483–1490, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. K. Loke, R. Cavallazzi, and S. Singh, “Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies,” Thorax, vol. 66, no. 8, pp. 699–708, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. T. P. Van Staa, H. G. M. Leufkens, L. Abenhaim, B. Zhang, and C. Cooper, “Use of oral corticosteroids and risk of fractures,” Journal of Bone and Mineral Research, vol. 15, no. 6, pp. 993–1000, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. R. S. Weinstein, “Glucocorticoid-induced osteoporosis and osteonecrosis,” Endocrinology and Metabolism Clinics of North America, vol. 41, no. 3, pp. 595–611, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. R. S. Weinstein, “Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity,” Bone, vol. 46, no. 3, pp. 564–570, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. L. C. Hofbauer and M. Rauner, “Minireview: live and let die: molecular effects of glucocorticoids on bone cells,” Molecular Endocrinology, vol. 23, no. 10, pp. 1525–1531, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. E. L. Humphrey, J. H. H. Williams, M. W. J. Davie, and M. J. Marshall, “Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells,” Bone, vol. 38, no. 5, pp. 652–661, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. B. L. Clarke, “Corticosteroid-induced osteoporosis: an update for dermatologists,” American Journal of Clinical Dermatology, vol. 13, no. 3, pp. 167–190, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Rossini, G. Orsolini, O. Viapiana, S. Adami, and D. Gatti, “Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros,” Endocrine, vol. 49, no. 3, pp. 620–627, 2015. View at Publisher · View at Google Scholar
  13. E. Kauh, L. Mixson, M.-P. Malice et al., “Prednisone affects inflammation, glucose tolerance, and bone, turnover within hours of treatment in healthy individuals,” European Journal of Endocrinology, vol. 166, no. 3, pp. 459–467, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. Z. Saidak, C. Le Henaff, S. Azzi et al., “Wnt/beta-catenin signaling mediates osteoblast differentiation triggered by peptide-induced alpha5beta1 integrin priming in mesenchymal skeletal cells,” The Journal of Biological Chemistry, vol. 290, no. 11, pp. 6903–6912, 2015. View at Publisher · View at Google Scholar
  15. S. F. Liou, J. H. Hsu, H. C. Chu, H. H. Lin, I. J. Chen, and J. L. Yeh, “KMUP-1 promotes osteoblast differentiation through cAMP and cGMP pathways and signaling of BMP-2/Smad1/5/8 and Wnt/β-catenin,” Journal of Cellular Physiology, vol. 230, no. 9, pp. 2038–2048, 2015. View at Publisher · View at Google Scholar
  16. P. Moutsatsou, E. Kassi, and A. G. Papavassiliou, “Glucocorticoid receptor signaling in bone cells,” Trends in Molecular Medicine, vol. 18, no. 6, pp. 348–359, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Chen, L. Zhang, Y. OuYang, H. Guan, Q. Liu, and B. Ni, “Glucocorticoid induced osteoblast apoptosis by increasing E4BP4 expression via up-regulation of Bim,” Calcified Tissue International, vol. 94, no. 6, pp. 640–647, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. M. A. Naves, R. M. R. Pereira, A. N. Comodo, É. L. F. C. de Alvarenga, V. F. Caparbo, and V. P. C. Teixeira, “Effect of dexamethasone on human osteoblasts in culture: involvement of β1 integrin and integrin-linked kinase,” Cell Biology International, vol. 35, no. 11, pp. 1147–1151, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Kuroki, H. Kaji, S. Kawano et al., “Short-term effects of glucocorticoid therapy on biochemical markers of bone metabolism in Japanese patients: a prospective study,” Journal of Bone and Mineral Metabolism, vol. 26, no. 3, pp. 271–278, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Mazziotti and A. Giustina, “Glucocorticoids and the regulation of growth hormone secretion,” Nature Reviews Endocrinology, vol. 9, no. 5, pp. 265–276, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Canalis, G. Mazziotti, A. Giustina, and J. P. Bilezikian, “Glucocorticoid-induced osteoporosis: pathophysiology and therapy,” Osteoporosis International, vol. 18, no. 10, pp. 1319–1328, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. S. C. Manolagas, “Steroids and osteoporosis: the quest for mechanisms,” Journal of Clinical Investigation, vol. 123, no. 5, pp. 1919–1921, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Henneicke, S. J. Gasparini, T. C. Brennan-Speranza, H. Zhou, and M. J. Seibel, “Glucocorticoids and bone: local effects and systemic implications,” Trends in Endocrinology and Metabolism, vol. 25, no. 4, pp. 197–211, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. B. D. Kahan, “Cyclosporine,” The New England Journal of Medicine, vol. 321, no. 25, pp. 1725–1738, 1989. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Epstein, “Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton,” Journal of Bone and Mineral Research, vol. 11, no. 1, pp. 1–7, 1996. View at Publisher · View at Google Scholar · View at Scopus
  26. A. M. Cueto-Manzano, S. Konel, A. J. Hutchison et al., “Bone loss in long-term renal transplantation: histopathology and densitometry analysis,” Kidney International, vol. 55, no. 5, pp. 2021–2029, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. J. E. Compston, “Osteoporosis after liver transplantation,” Liver Transplantation, vol. 9, no. 4, pp. 321–330, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Durieux, L. Mercadal, P. Orcel et al., “Bone mineral density and fracture prevalence in long-term kidney graft recipients,” Transplantation, vol. 74, no. 4, pp. 496–500, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Movsowitz, S. Epstein, M. Fallon, F. Ismail, and S. Thomas, “Cyclosporin-a in vivo produces severe osteopenia in the rat: effect of dose and duration of administration,” Endocrinology, vol. 123, no. 5, pp. 2571–2577, 1988. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Yeo, L. H. Beck, J. M. McDonald, and M. Zayzafoon, “Cyclosporin A elicits dose-dependent biphasic effects on osteoblast differentiation and bone formation,” Bone, vol. 40, no. 6, pp. 1502–1516, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Chen, X. Zheng, R. Zou, and J. Wang, “Effects of cyclosporin-a on rat skeletal biomechanical properties,” BMC Musculoskeletal Disorders, vol. 12, article 240, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. G. R. Goodman, I. R. Dissanayake, B. R. Sodam et al., “Immunosuppressant use without bone loss—implications for bone loss after transplantation,” Journal of Bone and Mineral Research, vol. 16, no. 1, pp. 72–78, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Ponticelli and A. Aroldi, “Osteoporosis after organ transplantation,” The Lancet, vol. 357, no. 9268, pp. 1623–1624, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Aroldi, A. Tarantino, G. Montagnino, B. Cesana, C. Cocucci, and C. Ponticelli, “Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: a prospective study,” Transplantation, vol. 63, no. 3, pp. 380–386, 1997. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Westenfeld, G. Schlieper, M. Wöltje et al., “Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis-implications for post-transplantation bone disease,” Nephrology Dialysis Transplantation, vol. 26, no. 12, pp. 4115–4123, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. S.-H. Jeon, S.-J. Kim, J.-S. Kim, and H.-S. Kang, “Immunosuppressant FK506 decreases the intracellular magnesium in the human osteoblast cell by inhibiting the ERK1/2 pathway,” Life Sciences, vol. 84, no. 1-2, pp. 23–27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. K. M. Park, J. E. Hay, S. G. Lee et al., “Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine,” Transplantation Proceedings, vol. 28, no. 3, pp. 1738–1740, 1996. View at Google Scholar · View at Scopus
  38. H. U. Stempfle, C. Werner, S. Echtler et al., “Rapid trabecular bone loss after cardiac transplantation using FK506 (tacrolimus)-based immunosuppression,” Transplantation Proceedings, vol. 30, no. 4, pp. 1132–1133, 1998. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Inoue, I. Kawamura, M. Matsuo et al., “Lesser reduction in bone mineral density by the immunosuppressant, FK506, compared with cyclosporine in rats,” Transplantation, vol. 70, no. 5, pp. 774–779, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Monegal, M. Navasa, N. Guañabens et al., “Bone mass and mineral metabolism in liver transplant patients treated with FK506 or Cyclosporine A,” Calcified Tissue International, vol. 68, no. 2, pp. 83–86, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Luo, Y. Shi, Y. Bai et al., “Impact of tacrolimus on bone metabolism after kidney transplantation,” International Immunopharmacology, vol. 13, no. 1, pp. 69–72, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. O. Alvarez-Garcia, E. Carbajo-Pérez, E. Garcia et al., “Rapamycin retards growth and causes marked alterations in the growth plate of young rats,” Pediatric Nephrology, vol. 22, no. 7, pp. 954–961, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. J. M. Campistol, D. W. Holt, S. Epstein, M. Gioud-Paquet, K. Rutault, and J. T. Burke, “Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus,” Transplant International, vol. 18, no. 9, pp. 1028–1035, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. D. F. Romero, F. J. Buchinsky, B. Rucinski et al., “Rapamycin: a bone sparing immunosuppressant?” Journal of Bone and Mineral Research, vol. 10, no. 5, pp. 760–768, 1995. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Glantschnig, J. E. Fisher, G. Wesolowski, G. A. Rodan, and A. A. Reszka, “M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase,” Cell Death and Differentiation, vol. 10, no. 10, pp. 1165–1177, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Kneissel, N.-H. Luong-Nguyen, M. Baptist et al., “Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts,” Bone, vol. 35, no. 5, pp. 1144–1156, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. I. R. Dissanayake, G. R. Goodman, A. R. Bowman et al., “Mycophenolate mofetil: a promising new immunosuppressant that does not cause bone loss in the rat,” Transplantation, vol. 65, no. 2, pp. 275–278, 1998. View at Google Scholar · View at Scopus
  48. H. P. Bryer, J. A. Isserow, E. C. Armstrong et al., “Azathioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the rat,” Journal of Bone and Mineral Research, vol. 10, no. 1, pp. 132–138, 1995. View at Google Scholar · View at Scopus
  49. J. Green, H. Debby, E. Lederer, M. Levi, H. K. Zajicek, and T. Bick, “Evidence for a pth-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia,” Kidney International, vol. 60, no. 3, pp. 1182–1196, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. P. Evenepoel, B. K. I. Meijers, H. de Jong et al., “Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 6, pp. 1829–1836, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. H. M. Alshayeb, M. A. Josephson, and S. M. Sprague, “CKD-mineral and bone disorder management in kidney transplant recipients,” American Journal of Kidney Diseases, vol. 61, no. 2, pp. 310–325, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. J. R. Weisinger, R. G. Carlini, E. Rojas, and E. Bellorin-Font, “Bone disease after renal transplantation,” Clinical Journal of the American Society of Nephrology, vol. 1, no. 6, pp. 1300–1313, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. T. R. Mikuls, B. A. Julian, A. Bartolucci, and K. G. Saag, “Bone mineral density changes within six months of renal transplantation,” Transplantation, vol. 75, no. 1, pp. 49–54, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. V. M. Brandenburg, D. Politt, M. Ketteler et al., “Early rapid loss followed by long-term consolidation characterizes the development of lumbar bone mineral density after kidney transplantation,” Transplantation, vol. 77, no. 10, pp. 1566–1571, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Pereira, S. Pedroso, L. Martins et al., “Bone mineral density after simultaneous kidney-pancreas transplantation: four years follow-up of 57 recipients,” Transplantation Proceedings, vol. 42, no. 2, pp. 555–557, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. K. Falkiewicz, M. Boratyńska, S. C. Zmonarski et al., “Evolution of bone disease at 2 years after transplantation: a single-center study,” Transplantation Proceedings, vol. 41, no. 8, pp. 3063–3066, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. N. Techawathanawanna, Y. Avihingsanon, K. Praditpornsilpa et al., “The prevalence and risk factors of osteoporosis in Thai renal-transplant patients,” Journal of the Medical Association of Thailand, vol. 88, supplement 4, pp. S103–S109, 2005. View at Google Scholar · View at Scopus
  58. A. K. Gupta, M. Huang, and G. V. Ramesh Prasad, “Determinants of bone mineral density in stable kidney transplant recipients,” Journal of Nephrology, vol. 25, no. 3, pp. 373–383, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Z. Molnar, M. S. Naser, C. M. Rhee, K. Kalantar-Zadeh, and S. Bunnapradist, “Bone and mineral disorders after kidney transplantation: therapeutic strategies,” Transplantation Reviews, vol. 28, no. 2, pp. 56–62, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. A. M. Ball, D. L. Gillen, D. Sherrard et al., “Risk of hip fracture among dialysis and renal transplant recipients,” The Journal of the American Medical Association, vol. 288, no. 23, pp. 3014–3018, 2002. View at Publisher · View at Google Scholar · View at Scopus
  61. L. M. Vautour, L. J. Melton III, B. L. Clarke, S. J. Achenbach, A. L. Oberg, and J. T. McCarthy, “Long-term fracture risk following renal transplantation: a population-based study,” Osteoporosis International, vol. 15, no. 2, pp. 160–167, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. S. Sukumaran Nair, C. R. Lenihan, M. E. Montez-Rath, D. W. Lowenberg, G. M. Chertow, and W. C. Winkelmayer, “Temporal trends in the incidence, treatment and outcomes of hip fracture after first kidney transplantation in the United States,” American Journal of Transplantation, vol. 14, no. 4, pp. 943–951, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Patel, J. T. C. Kwan, E. McCloskey et al., “Prevalence and causes of low bone density and fractures in kidney transplant patients,” Journal of Bone and Mineral Research, vol. 16, no. 10, pp. 1863–1870, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. K. L. Naylor, A. H. Li, N. N. Lam, A. B. Hodsman, S. A. Jamal, and A. X. Garg, “Fracture risk in kidney transplant recipients: a systematic review,” Transplantation, vol. 95, no. 12, pp. 1461–1470, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. P. Perrin, S. Caillard, R. M. Javier et al., “Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation,” American Journal of Transplantation, vol. 13, no. 10, pp. 2653–2663, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. L. E. Nikkel, S. P. Iyer, S. Mohan et al., “Pancreas-kidney transplantation is associated with reduced fracture risk compared with kidney-alone transplantation in men with type 1 diabetes,” Kidney International, vol. 83, no. 3, pp. 471–478, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. T. K. M. Wang, S. O'Sullivan, G. D. Gamble, and P. N. Ruygrok, “Bone density in heart or lung transplant recipients-a longitudinal study,” Transplantation Proceedings, vol. 45, no. 6, pp. 2357–2365, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Dolgos, A. Hartmann, G. A. Isaksen et al., “Osteoporosis is a prevalent finding in patients with solid organ failure awaiting transplantation—a population based study,” Clinical Transplantation, vol. 24, no. 5, pp. 145–152, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. J. S. Muchmore, D. K. C. Cooper, Y. Ye, V. T. Schlegel, and N. Zuhdi, “Loss of vertebral bone density in heart transplant patients,” Transplantation Proceedings, vol. 23, no. 1, part 2, pp. 1184–1185, 1991. View at Google Scholar · View at Scopus
  70. E. Stein, P. Ebeling, and E. Shane, “Post-transplantation osteoporosis,” Endocrinology and Metabolism Clinics of North America, vol. 36, no. 4, pp. 937–963, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. J. Van Cleemput, W. Deanen, J. Nijs, P. Geusens, J. Dequeker, and J. Vanhaecke, “Timing and quantification of bone loss in cardiac transplant recipients,” Transplant International, vol. 8, no. 3, pp. 196–200, 1995. View at Publisher · View at Google Scholar · View at Scopus
  72. A. Cohen and E. Shane, “Osteoporosis after solid organ and bone marrow transplantation,” Osteoporosis International, vol. 14, no. 8, pp. 617–630, 2003. View at Publisher · View at Google Scholar · View at Scopus
  73. P. R. Ebeling, “Approach to the patient with transplantation-related bone loss,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 5, pp. 1483–1490, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. G. Leidig-Bruckner, S. Hosch, P. Dodidou et al., “Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study,” The Lancet, vol. 357, no. 9253, pp. 342–347, 2001. View at Publisher · View at Google Scholar · View at Scopus
  75. E. Shane, M. Rivas, R. B. Staron et al., “Fracture after cardiac transplantation: a prospective longitudinal study,” The Journal of Clinical Endocrinology & Metabolism, vol. 81, no. 5, pp. 1740–1746, 1996. View at Publisher · View at Google Scholar · View at Scopus
  76. E. Shane, M. Rivas, R. B. Staron et al., “Fracture after cardiac transplantation: a prospective longitudinal study,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 5, pp. 1740–1746, 1996. View at Publisher · View at Google Scholar · View at Scopus
  77. K. Kerschan-Schindl, M. Ruzicka, S. Mahr et al., “Unexpected low incidence of vertebral fractures in heart transplant recipients: analysis of bone turnover,” Transplant International, vol. 21, no. 3, pp. 255–262, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. L. D. Carbonare, M. Zanatta, V. Braga et al., “Densitometric threshold and vertebral fractures in heart transplant patients,” Transplantation, vol. 92, no. 1, pp. 106–111, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. J. Collier, “Bone disorders in chronic liver disease,” Hepatology, vol. 46, no. 4, pp. 1271–1278, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. I. Loria, C. Albanese, M. Giusto et al., “Bone disorders in patients with chronic liver disease awaiting liver transplantation,” Transplantation Proceedings, vol. 42, no. 4, pp. 1191–1193, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. O. I. Giouleme, T. A. Vyzantiadis, N. L. Nikolaidis et al., “Pathogenesis of osteoporosis in liver cirrhosis,” Hepato-Gastroenterology, vol. 53, no. 72, pp. 938–943, 2006. View at Google Scholar · View at Scopus
  82. R. P. Sokhi, A. Anantharaju, R. Kondaveeti, S. D. Creech, K. K. Islam, and D. H. Van Thiel, “Bone mineral density among cirrhotic patients awaiting liver transplantation,” Liver Transplantation, vol. 10, no. 5, pp. 648–653, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. X. L. Bai, T. B. Liang, L. H. Wu et al., “Elevation of intact parathyroid hormone level is a risk factor for low bone mineral density in pretransplant patients with liver diseases,” Transplantation Proceedings, vol. 39, no. 10, pp. 3182–3185, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. M. M. J. Guichelaar, R. Kendall, M. Malinchoc, and J. E. Hay, “Bone mineral density before and after OLT: long-term follow-up and predictive factors,” Liver Transplantation, vol. 12, no. 9, pp. 1390–1402, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. J. E. Hay, “Osteoporosis in liver diseases and after liver transplantation,” Journal of Hepatology, vol. 38, no. 6, pp. 856–865, 2003. View at Publisher · View at Google Scholar · View at Scopus
  86. A. Monegal, M. Navasa, N. Guañabens et al., “Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics,” Osteoporosis International, vol. 12, no. 6, pp. 484–492, 2001. View at Publisher · View at Google Scholar · View at Scopus
  87. L. F. Baccaro, I. F. S. F. Boin, A. O. Pedro et al., “Decrease in bone mass in women after liver transplantation: associated factors,” Transplantation Proceedings, vol. 43, no. 4, pp. 1351–1356, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. M. Ninkovic, S. J. Skingle, P. W. P. Bearcroft, N. Bishop, G. J. M. Alexander, and J. E. Compston, “Incidence of vertebral fractures in the first three months after orthotopic liver transplantation,” European Journal of Gastroenterology and Hepatology, vol. 12, no. 8, pp. 931–935, 2000. View at Publisher · View at Google Scholar · View at Scopus
  89. N. Guanabens and A. Pares, “Liver and bone,” Archives of Biochemistry and Biophysics, vol. 503, no. 1, pp. 84–94, 2010. View at Google Scholar
  90. L. Graat-Verboom, E. F. M. Wouters, F. W. J. M. Smeen, B. E. E. M. van den Borne, R. Lunde, and M. A. Spruit, “Current status of research on osteoporosis in COPD: a systematic review,” European Respiratory Journal, vol. 34, no. 1, pp. 209–218, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. S. Maggi, P. Siviero, S. Gonnelli et al., “Osteoporosis risk in patients with chronic obstructive pulmonary disease: the EOLO study,” Journal of Clinical Densitometry, vol. 12, no. 3, pp. 345–352, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. D. Jastrzebski, W. Lutogniewska, M. Ochman et al., “Osteoporosis in patients referred for lung transplantation,” European journal of medical research, vol. 15, supplement 2, pp. 68–71, 2010. View at Google Scholar · View at Scopus
  93. R. M. Reed, R. A. Wise, A. S. Dobs, N. Lechtzin, and R. E. Girgis, “Elevated HDL cholesterol levels are associated with osteoporosis in lung transplant candidates with chronic obstructive pulmonary disease,” Respiratory Medicine, vol. 104, no. 12, pp. 1943–1950, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. S. L. Ferrari, L. P. Nicod, J. Hamacher et al., “Osteoporosis in patients undergoing lung transplantation,” European Respiratory Journal, vol. 9, no. 11, pp. 2378–2382, 1996. View at Publisher · View at Google Scholar · View at Scopus
  95. A. Hariman, C. Alex, A. Heroux, and P. Camacho, “Incidence of fractures after cardiac and lung transplantation: a single center experience,” Journal of Osteoporosis, vol. 2014, Article ID 573041, 8 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  96. B. C. Cahill, M. K. O'Rourke, S. Parker, J. C. Stringham, S. V. Karwande, and T. P. Knecht, “Prevention of bone loss and fracture after lung transplantation,” Transplantation, vol. 72, no. 7, pp. 1251–1255, 2001. View at Publisher · View at Google Scholar · View at Scopus
  97. B. Ewers, A. Gasbjerg, C. Moelgaard, A. M. Frederiksen, and P. Marckmann, “Vitamin D status in kidney transplant patients: need for intensified routine supplementation,” American Journal of Clinical Nutrition, vol. 87, no. 2, pp. 431–437, 2008. View at Google Scholar · View at Scopus
  98. N. Kathryn Briffa, A. M. Keogh, P. N. Sambrook, and J. A. Eisman, “Reduction of immunosuppressant therapy requirement in heart transplantation by calcitriol,” Transplantation, vol. 75, no. 12, pp. 2133–2134, 2003. View at Publisher · View at Google Scholar · View at Scopus
  99. A. Torres, S. García, A. Gómez et al., “Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation,” Kidney International, vol. 65, no. 2, pp. 705–712, 2004. View at Publisher · View at Google Scholar · View at Scopus
  100. R. G. L. De Sévaux, A. J. Hoitsma, F. H. M. Corstens, and J. F. M. Wetzels, “Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study,” Journal of the American Society of Nephrology, vol. 13, no. 6, pp. 1608–1614, 2002. View at Publisher · View at Google Scholar · View at Scopus
  101. P. Sambrook, N. K. Henderson, A. Keogh et al., “Effect of calcitriol on bone loss after cardiac or lung transplantation,” Journal of Bone and Mineral Research, vol. 15, no. 9, pp. 1818–1824, 2000. View at Publisher · View at Google Scholar · View at Scopus
  102. S. C. Palmer, D. O. McGregor, and G. F. Strippoli, “Interventions for preventing bone disease in kidney transplant recipients,” Cochrane Database of Systematic Reviews, no. 3, Article ID CD005015, 2007. View at Google Scholar · View at Scopus
  103. Z. Wang, Z. Han, J. Tao et al., “Clinical efficacy and safety of pamidronate therapy on bone mass density in early post-renal transplant period: a meta-analysis of randomized controlled trials,” PLoS ONE, vol. 9, no. 9, Article ID e108106, 2014. View at Publisher · View at Google Scholar · View at Scopus
  104. A. Monegal, N. Guanabens, M. J. Suarez et al., “Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial,” Transplant International, vol. 22, no. 2, pp. 198–206, 2009. View at Google Scholar
  105. P. Dodidou, T. Bruckner, S. Hosch et al., “Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation,” Osteoporosis International, vol. 14, no. 1, pp. 82–89, 2003. View at Publisher · View at Google Scholar · View at Scopus
  106. K. T. Smerud, S. Dolgos, I. C. Olsen et al., “A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation,” American Journal of Transplantation, vol. 12, no. 12, pp. 3316–3325, 2012. View at Publisher · View at Google Scholar · View at Scopus
  107. A. Fahrleitner-Pammer, J. C. Piswanger-Soelkner, T. R. Pieber et al., “Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial,” Journal of Bone and Mineral Research, vol. 24, no. 7, pp. 1335–1344, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. D. Wagner, K. Amrein, H. P. Dimai et al., “Ibandronate and calcitriol reduces fracture risk, reverses bone loss, and normalizes bone turnover after lTX,” Transplantation, vol. 93, no. 3, pp. 331–336, 2012. View at Publisher · View at Google Scholar · View at Scopus
  109. M. Haas, Z. Leko-Mohr, P. Roschger et al., “Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation,” Kidney International, vol. 63, no. 3, pp. 1130–1136, 2003. View at Publisher · View at Google Scholar · View at Scopus
  110. W.-H. Huang, S.-Y. Lee, C.-H. Weng, and P.-C. Lai, “Use of alendronate sodium (Fosamax) to ameliorate osteoporosis in renal transplant patients: a case-control study,” PLoS ONE, vol. 7, no. 11, Article ID e48481, 2012. View at Publisher · View at Google Scholar · View at Scopus
  111. S. Yamamoto, A. Suzuki, H. Sasaki et al., “Oral alendronate can suppress bone turnover but not fracture in kidney transplantation recipients with hyperparathyroidism and chronic kidney disease,” Journal of Bone and Mineral Metabolism, vol. 31, no. 1, pp. 116–122, 2013. View at Publisher · View at Google Scholar · View at Scopus
  112. H.-H. Wang, P.-C. Chang, S.-H. Chu et al., “Osteoporosis after kidney transplantation: preliminary report from a single center,” Transplantation Proceedings, vol. 40, no. 7, pp. 2412–2413, 2008. View at Publisher · View at Google Scholar · View at Scopus
  113. S. R. Cummings, J. S. Martin, M. R. McClung et al., “Denosumab for prevention of fractures in postmenopausal women with osteoporosis,” The New England Journal of Medicine, vol. 361, no. 8, pp. 756–765, 2009. View at Publisher · View at Google Scholar · View at Scopus
  114. J. W. Mandema, J. Zheng, C. Libanati, and R. J. J. Perez, “Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis,” Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 10, pp. 3746–3755, 2014. View at Publisher · View at Google Scholar · View at Scopus
  115. K. G. Saag, E. Shane, S. Boonen et al., “Teriparatide or alendronate in glucocorticoid-induced osteoporosis,” The New England Journal of Medicine, vol. 357, no. 20, pp. 2028–2039, 2007. View at Publisher · View at Google Scholar · View at Scopus
  116. D. Cejka, T. Benesch, C. Krestan et al., “Effect of teriparatide on early bone loss after kidney transplantation,” American Journal of Transplantation, vol. 8, no. 9, pp. 1864–1870, 2008. View at Publisher · View at Google Scholar · View at Scopus
  117. E. L. Nogueira, A. C. Costa, A. Santana et al., “Teriparatide efficacy in the treatment of severe hypocalcemia after kidney transplantation in parathyroidectomized patients: a series of five case reports,” Transplantation, vol. 92, no. 3, pp. 316–320, 2011. View at Publisher · View at Google Scholar · View at Scopus
  118. H. Isoniemi, J. Appelberg, C.-G. Nilsson, P. Mäkelä, J. Risteli, and K. Höckerstedt, “Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis. A 2-year follow-up study,” Journal of Hepatology, vol. 34, no. 2, pp. 299–305, 2001. View at Publisher · View at Google Scholar · View at Scopus
  119. B. Pietrzak, A. Cyganek, Z. Jabiry-Zieniewicz et al., “Safety and efficacy of hormonal therapy in menopausal kidney-allograft recipients,” Transplantation Proceedings, vol. 38, no. 1, pp. 184–187, 2006. View at Publisher · View at Google Scholar · View at Scopus